Potassium aminobenzoate
Brand names: Potaba
Potassium aminobenzoate is a member of the vitamin B complex group that has been used in fibrotic skin and connective-tissue conditions such as Peyronie's disease and scleroderma.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
Its mechanism is not fully established, but it is thought to have antifibrotic effects, possibly by influencing oxygen uptake and connective-tissue metabolism.
Prescribing in practice
- Gastrointestinal upset is common, and treatment should be stopped if intake of food or fluids cannot be maintained, given the theoretical risk of hypoglycaemia.
- It should be used with caution in renal impairment because of its potassium content.
- Treatment is typically prolonged, and adherence over an extended period is needed for any benefit.
Monitoring
Monitor renal function and for gastrointestinal tolerance during prolonged courses.
Counselling the patient
- Take the medicine with food to reduce stomach upset.
- Stop the medicine and seek advice if you cannot eat or drink normally.
- Benefit, if any, develops only over a long period of treatment.
Evidence & guidelines
Evidence for potassium aminobenzoate is limited and largely historical, and it is not a first-line therapy for these conditions.
Reference: SmPC; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.